WallStreetZenWallStreetZen

NASDAQ: COAG
Hemab Therapeutics Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for COAG

Based on 5 analysts offering 12 month price targets for Hemab Therapeutics Holdings Inc

Min Forecast
$36.00-10.25%
Avg Forecast
$51.40+28.15%
Max Forecast
$64.00+59.56%

Should I buy or sell COAG stock?

Based on 5 analysts offering ratings for Hemab Therapeutics Holdings Inc.

Strong Buy
Strong Buy
2 analysts 40%
Buy
3 analysts 60%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although COAG's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates COAG as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their COAG stock forecasts and price targets.

COAG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-12
lockedlocked$00.00+00.00%2026-08-11
lockedlocked$00.00+00.00%2026-07-13
lockedlocked$00.00+00.00%2026-05-26
lockedlocked$00.00+00.00%2026-05-26

1 of 1

Forecast return on equity

Is COAG forecast to generate an efficient return?

Company
-39.96%
Industry
18.55%
Market
169.71%
COAG's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is COAG forecast to generate an efficient return on assets?

Company
-38.81%
Industry
23.41%
COAG is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

COAG earnings per share forecast

What is COAG's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$3.22
Avg 2 year Forecast
-$2.63
Avg 3 year Forecast
-$3.33

COAG revenue forecast

What is COAG's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$2.0M

COAG vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
COAG$40.11$51.40+28.15%Strong Buy
FTRE$19.73$22.00+11.51%Strong Buy
BHVN$12.34$15.20+23.18%Buy
GHRS$27.55$44.50+61.52%Strong Buy
ZYME$26.05$39.14+50.26%Strong Buy
View Top Biotech Stocks

Hemab Therapeutics Holdings Stock Forecast FAQ

Is Hemab Therapeutics Holdings Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: COAG) stock is to Strong Buy COAG stock.

Out of 5 analysts, 2 (40%) are recommending COAG as a Strong Buy, 3 (60%) are recommending COAG as a Buy, 0 (0%) are recommending COAG as a Hold, 0 (0%) are recommending COAG as a Sell, and 0 (0%) are recommending COAG as a Strong Sell.

If you're new to stock investing, here's how to buy Hemab Therapeutics Holdings stock.

What is COAG's earnings growth forecast for 2026-2028?

(NASDAQ: COAG) Hemab Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.35%.

Hemab Therapeutics Holdings's earnings in 2026 is N/A.On average, 7 Wall Street analysts forecast COAG's earnings for 2026 to be -$150,207,483, with the lowest COAG earnings forecast at -$147,862,535, and the highest COAG earnings forecast at -$146,162,214. On average, 7 Wall Street analysts forecast COAG's earnings for 2027 to be -$122,927,607, with the lowest COAG earnings forecast at -$128,635,828, and the highest COAG earnings forecast at -$117,224,058.

In 2028, COAG is forecast to generate -$155,686,815 in earnings, with the lowest earnings forecast at -$165,715,906 and the highest earnings forecast at -$136,843,147.

What is COAG's revenue growth forecast for 2026-2028?

(NASDAQ: COAG) Hemab Therapeutics Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.52%.

Hemab Therapeutics Holdings's revenue in 2026 is N/A.On average, 7 Wall Street analysts forecast COAG's revenue for 2026 to be $0, with the lowest COAG revenue forecast at $0, and the highest COAG revenue forecast at $0. On average, 7 Wall Street analysts forecast COAG's revenue for 2027 to be $0, with the lowest COAG revenue forecast at $0, and the highest COAG revenue forecast at $0.

In 2028, COAG is forecast to generate $91,742,598 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $377,667,466.

What is COAG's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: COAG) forecast ROA is -38.81%, which is lower than the forecast US Biotechnology industry average of 23.41%.

What is COAG's Price Target?

According to 5 Wall Street analysts that have issued a 1 year COAG price target, the average COAG price target is $51.40, with the highest COAG stock price forecast at $64.00 and the lowest COAG stock price forecast at $36.00.

On average, Wall Street analysts predict that Hemab Therapeutics Holdings's share price could reach $51.40 by Aug 12, 2027. The average Hemab Therapeutics Holdings stock price prediction forecasts a potential upside of 28.15% from the current COAG share price of $40.11.

What is COAG's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: COAG) Hemab Therapeutics Holdings's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that COAG's EPS will be -$3.22 for 2026, with the lowest EPS forecast at -$3.17, and the highest EPS forecast at -$3.13. On average, analysts forecast that COAG's EPS will be -$2.63 for 2027, with the lowest EPS forecast at -$2.75, and the highest EPS forecast at -$2.51. In 2028, COAG's EPS is forecast to hit -$3.33 (min: -$3.55, max: -$2.93).

What is COAG's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: COAG) forecast ROE is -39.96%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.